

## Wessex Regional Genetics Laboratory Publications 2021

Bruford EA, Antonescu CR, Carroll AJ, Chinnaiyan A, Cree IA, **Cross NCP**, Dalglish R, Gale RP, Harrison CJ, Hastings RJ, Huret JL, Johansson B, Le Beau M, Mecucci C, Mertens F, Verhaak R, Mitelman F. 2021. HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. *Leukemia* **35**: 3040-3043 [PMID: 34615987].

**Bunyan DJ**, Gevers E, **Hobbs JI**, **Duncan-Flavell PJ**, **Howarth RJ**, Holder-Espinasse M, Klee P, Van-Heurk R, Lemmens L, Carminho-Rodrigues MT, Mohamed Z, Goturu A, Hughes CR, Ajzensztein M, **Thomas NS**. 2021. Rare dosage abnormalities flanking the *SHOX* gene. *Egypt. J. Med. Hum. Genet.* **22**: 89.

Buonocore F, Maharaj A, Qamar Y, Koehler K, Suntharalingham JP, Chan LF, Ferraz-de-Souza B, Hughes CR, Lin L, Prasad R, Allgrove J, Andrews ET, Buchanan CR, Cheetham TD, Crowne EC, Davies JH, Gregory JW, Hindmarsh PC, Hulse T, Krone NP, Shah P, Shaikh MG, Roberts C, Clayton PE, Dattani MT, **Thomas NS**, Huebner A, Clark AJ, Metherell LA, Achermann JC. 2021. Genetic analysis of pediatric primary adrenal insufficiency of unknown etiology: 25 years' experience in the United Kingdom. *J. Endocr. Soc.* **5** (8): 1-15 [PMID: 34258490].

**Cross NCP**, Godfrey AL, Cargo C, Garg M, Mead AJ. 2021. A British Society for Haematology Good Practice Paper. The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders. *Br. J. Haematol.* **195** (3): 338-351 [PMID: 34409596].

Cubuk C, Garrett A, Choi S, King L, Loveday C, Torr B, Burghel GJ, Durkie M, **Callaway A**, Robinson R, Drummond J, Berry I, Wallace A, Eccles D, Tischkowitz M, Whiffin N, Ware JS, Hanson H, Turnbull C; CanVIG-UK. 2021. Clinical likelihood ratios and balanced accuracy for 44 *in silico* tools against multiple large-scale functional assays of cancer susceptibility genes. *Genet Med.* **23** (11): 2096-2104 [PMID: 34230640].

Edgerley K, Barnicoat A, Offiah AC, Calder AD, Mankad K, **Thomas NS**, **Bunyan DJ**, Williams M, Buxton C, Majumdar A, Vijayakumar K, Hilliard T, Turner J, Burren CP, Monsell F, Smithson SF. 2021. *Am. J. Med. Genet.* **185A**: 1228-1235 [PMID: 33439541].

Galatà G, García-Montero AC, Kristensen T, Dawoud AAZ, Muñoz-González JI, Meggendorfer M, Guglielmelli P, Hoade Y, Alvarez-Twose I, Gieger C, Strauch K, Ferrucci L, Tanaka T, Bandinelli S, Schnurr TM, Haferlach T, Broesby-Olsen S, Vestergaard H, Møller MB, Bindslev-Jensen C, Vannucchi AM, Orfao A, Radia D, Reiter A, **Chase AJ**, **Cross NCP**, Tapper WJ. 2021. Genome-wide association study identifies novel susceptibility loci for *KIT* D816V positive mastocytosis. *Am. J. Hum. Genet.* **108** (2): 284-294 [PMID: 33421400].

Gale RP, Hochhaus A, **Cross NCP**, Harrison CJ. 2021. HGNC nomenclature for fusion genes. *Leukemia* **35**: 3039 [PMID: 34611300].

Garrett A, Durkie M, **Callaway A**, Burghel GJ, Robinson R, Drummond J, Torr B, Cubuk C, Berry IR, Wallace AJ, Ellard S, Eccles DM, Tischkowitz M, Hanson H, Turnbull C;

CanVIG-UK. 2021. Combining evidence for and against pathogenicity for variants in cancer susceptibility genes: CanVIG-UK consensus recommendations. *J Med Genet.* **58** (5): 297-304. [PMID: 33208383].

McLornan DP, Boluda JCH, Czerw T, **Cross NCP**, Joachim Deeg H, Ditschkowski M, Moonim MT, Polverelli N, Robin M, Aljurf M, Conneally E, Hayden P, Yakoub-Agha I. 2021. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. *Leukemia* **35** (9): 2445-2459 [PMID 34040148]; *Erratum Leukemia* **35** (12): 3625 [PMID: 34471230].

Michail O, McCallion P, McGimpsey J, Hindley A, Greenfield G, McAllister R, Feerick J, Arnold C, **Cross NCP**, Cuthbert R, McMullin MF, Catherwood MA. 2021. Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort. *J. Clin. Pathol.* **74** (12): 808-811 [PMID: 33144355].

Milojkovic D, **Cross NCP**, Ali S, Byrne J, Campbell G, Dignan FL, Drummond M, Huntly B, Marshall S, McMullin MF, Neelakantan P, Raghavan M, Sivakumaran M, Tighe J, Wandroo F, Willis F, Glen F, Fildes L, Collington SJ, Ryan J, Clark RE, Mead AJ. 2021. Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. *Br. J. Haematol.* **192** (1): 62-74.

Naumann N, Lübke J, Baumann S, Schwaab J, Hoffmann O, Kreil S, Dangelo V, Reiter L, Bugert P, Kristensen T, Sotlar K, Haselmann V, Schneider S, Metzgeroth G, Weiss C, Popp HD, Fabarius A, Hofmann W-K, **Cross NCP**, Reiter A, Jawhar M. 2021. Adverse prognostic impact of the *KIT* D816V transcriptional activity in advanced systemic mastocytosis. *Int. J. Mol. Sci.* **22** (5): 2562 [PMID: 33806359].

Naumann N, Lübke J, Shomali W, Reiter L, Horny HP, Jawhar M, Dangelo V, Fabarius A, Metzgeroth G, Kreil S, Sotlar K, Oni C, Harrison C, Hofmann WK, **Cross NCP**, Valent P, Radia D, Gotlib J, Reiter A, Schwaab J. 2021. Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations. *Br. J. Haematol.* **194** (2): 344-354 [PMID: 34060083].

Nazlamova L, **Thomas NS**, Cheung M-K, Legebeke J, Lord J, Pengelly RJ, Tapper WJ, Wheway G. 2021. A CRISPR and high-content imaging assay compliant with ACMG/AMP guidelines for clinical variant interpretation in ciliopathies. *Hum. Genet.* **140** (4): 593-607 [PMID: 33095315].

**Salmon M, White HE, Cross NCP**, Hochhaus A. 2021. Standardization of molecular monitoring for Chronic Myeloid Leukemia: 2021 update. In: Hehlmann R. (ed.), *Hematologic Malignancies: Chronic Myeloid Leukemia*, 105-117 (Springer).

Schäfer V, **White HE**, Gerrard G, Möbius S, Saussele S, Franke GN, Mahon FX, Talmaci R, Colomer D, Soverini S, Machova Polakova K, **Cross NCP**, Hochhaus A, Ernst T. 2021. Assessment of individual molecular response in chronic myeloid leukemia patients with

atypical *BCR-ABL1* fusion transcripts: recommendations by the EUTOS cooperative network. *J. Cancer Res. Clin. Oncol.* **147** (10): 3081-3089 [PMID: 33677711].

Shoemark A, Rubbo B, Legendre M, Fassad MR, Haarman EG, Best S, Bon ICM, Brandsma J, Burgel P-R, Carlsson G, Carr SB, Carroll M, Edwards M, Escudier E, Honoré I, Hunt D, Jouvion G, Loebinger MR, Maitre B, Morris-Rosendahl D, Papon J-F, Parsons CM, Patel MP, **Thomas NS**, Thouvenin G, Walker WT, Wilson R, Hogg C, Mitchison HM, Lucas JS. 2021. Topological data analysis reveals genotype-phenotype relationships in primary ciliary dyskinesia. *Eur. Respir. J.* **58** (2): 2002359. [PMID: 33479112].

Steele L, Hill K, **Cross NCP**, Cooper HL. 2021. Possible transmission of Laugier-Hunziker syndrome by allogeneic peripheral blood stem cell transplantation. *Clin. Exp. Dermatol.* **46** (2): 400-402 [PMID: 33217072].

Trevino CE, Rounds JC, Charen K, Shubeck L, Hipp HS, Spencer JB, Johnston HR, Cutler DJ, Zwick ME, Epstein MP, Murray A, **Macpherson JN**, Mila M, Rodriguez-Revenga L, Berry-Kravis E, Hall DA, Leehey MA, Liu Y, Welt C, Warren ST, Sherman SL, Jin P, Allen EG. 2021. Identifying susceptibility genes for primary ovarian insufficiency on the high-risk genetic background of a fragile X premutation. *Fertil. Steril.* **116** (3): 843-854 [PMID: 34016428].

Wheway G, **Thomas NS**; Carroll M, Coles J, Doherty R, Genomics England Research Consortium, Goggin P, Green B, Harris A, Hunt D, Jackson CL, Lord J, Mennella V, Thompson J, Walker WT, Lucas JS. 2021. Whole genome sequencing in the diagnosis of primary ciliary dyskinesia. *BMC Med. Genomics* **14** (1): 234 [PMID: 34556108].